Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis

Sonia Villani, Nunzia Zanotta, Federico Ambrogi, Manola Comar, Diego Franciotta, Maria Dolci, Carolina Cason, Rosalia Ticozzi, Pasquale Ferrante, Serena Delbue

Research output: Contribution to journalArticle

Abstract

Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.

Original languageEnglish
Pages (from-to)91-96
Number of pages6
JournalJournal of Neuroimmunology
Volume310
DOIs
Publication statusPublished - Sep 15 2017

Keywords

  • Cytokines
  • JC virus
  • Natalizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this